Skip to content

Optimal care at the end of life

Optimal care at the end of life - OPAL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00015108
Enrollment
115
Registered
2019-01-22
Start date
2018-10-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with life-limiting, chronic progressive oncological and non-oncological diseases, being in general practitioners care in the chosen Region.

Interventions

Group 1: a. Stakeholder in the targeted health region, experts interviews for (t=0) Exploration the health region. Infrastructure, care experiences, care situation and cooperation between different a

Sponsors

Medizinische Hochschule Hannover
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: a. General practitioners Located GPs in targeted region, who are registered in the region within the duration of the project (independent by sex) b. Deceased patients of targeted GPs practice Deceased as a result of life-limiting, chronic progressive oncological and non-oncological diseases within period of observation and while in GPs care, age > 18 (independent of sex) c. Remained relatives of deceased patients in GPs practice Age > 18 and direct contact to deceased patient in the last phase of life (independent of sex) d. Stakeholder in health region Employed at least 1 year at interface to GPs practice (nursing service, nursing homes, hospitals, surgery) (independent of sex) e. Health insurance data Patient deceased as a result of life-limiting, chronic progressive oncological and non-oncological diseases within ZIP-Code of the targeted Region in 2016/2017 (t=0) or 2019/2020 (t=1), continuously assured, age > 18 (independent of sex)

Exclusion criteria

Exclusion criteria: b. and e.: Sudden death, which is not related to a life-limiting, chronic progressive oncological and non-oncological disease (e.g. traffic accident, heart attack without diagnosis of coronary heart disease)

Design outcomes

Primary

MeasureTime frame
a.) Optimized care at the end of life- General practitioners perspective: GP-EoLC-I, written survey of the project’s general practitioners – Dimensions: clinical practice of the general practitioners, organization of palliative care (t=0 six months pre interventionem, t=1 six month post-interventionem)

Secondary

MeasureTime frame
a. Optimized care in the last phase of life – relatives perspective Situation of care, involvement in therapeutical decisions, Advanced-Care-Planning, consideration of therapeutic preferences, preferred place of living in the end of life and place of death, after- death- interviews (t0 six month pre interventionem, t1 six month post interventionem) b. Optimized care of patients at the end of life (Palliative-) Care- Indicators at the end of life, similar to the Bertelsmann-Stiftung’s facts-checking (2015) about routine data of the GP practice in the health region (t0 six month pre interventionem, t1 six month post interventionem) and AOK-data for a regional comparative analysis (t0 twelve month pre interventionem, t1 twelve month post interventionem) - Chemotherapy while the last month of life of cancer patients, - PEG-device while the last three month of life of dementia-patient, - Number of hospital stays and days of hospital care in the last 6 month of life, - Number of patients with EBM-treatments within AAPV, - Number of SAPV-first-prescription’s and SAPV-first-prescription’s within the last three days of life, - Average duration of SAPV-treatments, - Number of patients who deceased in hospital c. Acceptance and usage of SPICT: Number of cases in GP practice, where SPICT was used to assess the palliative situation, analysis of documents of patient files (6 month post interventionem) d. GP’s awareness and sensibility for palliative situations: Number of patients, who are eligible for palliative care, number of AAPV-cases and SAPV-prescriptions, analysis of documents of patients files and GKV-data (t0 six month pre interventionem, t1 post interventionem) e. Effectiveness- practical consequences for GPs: Number of initiate interventions for patients with life-limiting, chronic progressive oncological and non-oncological diseases, e.g. medication review, Advanced-Palliative-Care, structured survey of demand, prescription of SAPV, analysis of documents of pat

Countries

Germany

Contacts

Public ContactKambiz Afshar

Medizinische Hochschule Hannover

afshar.kambiz@mh-hannover.de+49 511 532-2744

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 24, 2026